ArticleNPJ science of food2025
Administration of green tea polyphenols mitigates iron-overload-induced bone loss in a β-thalassemia mouse model.
Article in NPJ science of food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Osteoporosis is a frequent complication in β-thalassemia patients with iron overload, primarily driven by iron-induced oxidative damage and subsequent bone loss. Strategies that promote iron elimination and mitigate oxidative stress may help slow the progression of osteoporosis. Green tea extract (GTE, Camellia sinensis), enriched in epigallocatechin-3-gallate (EGCG), has both antioxidant and iron-chelating activities. This study assessed the effects of GTE on bone health in β-thalassemia knockout mice subjected to 4 weeks of iron dextran injections, followed by 2 months of daily oral treatment with deionized water, deferiprone (50 mg/kg), GTE (50 mg EGCG/kg), the combination of deferiprone and GTE, EGCG (50 mg/kg), or vitamin D3 (0.5 μg/kg ). GTE treatment reduced systemic iron burden, malondialdehyde, alkaline phosphatase, and parathyroid hormone, while improving femoral microarchitecture, bone mineral density, plasma calcium, and bone morphogenetic protein expression. These findings suggest GTE protects against iron-induced bone loss through combined chelation and antioxidation, supporting its potential as a therapeutic strategy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.